TherapeuticsMD (TXMD) Long-Term Deferred Tax (2018 - 2024)

TherapeuticsMD's Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $167.4 million for Q4 2024.

• Quarterly Long-Term Deferred Tax rose 5.9% year-over-year to $167.4 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $167.4 million (up 5.9% YoY) and the FY2024 annual result came in at $167.4 million, up 5.9% from the prior year.
• Long-Term Deferred Tax was $167.4 million for Q4 2024 at TherapeuticsMD, up from $158.0 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $176.6 million in Q4 2022 and bottomed at $158.0 million in Q4 2023.
• A 3-year average of $167.3 million and a median of $167.4 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2023 — Long-Term Deferred Tax slipped 10.53% — and 2024, when it increased 5.9%.
• TherapeuticsMD's Long-Term Deferred Tax stood at $176.6 million in 2022, then declined by 10.53% to $158.0 million in 2023, then increased by 5.9% to $167.4 million in 2024.
• Business Quant data shows TXMD's Long-Term Deferred Tax at $167.4 million in Q4 2024, $158.0 million in Q4 2023, and $176.6 million in Q4 2022.